These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 26070474)

  • 1. Gonadotropin-releasing hormone antagonist: A real advantage?
    Kimura T; Sasaki H; Akazawa K; Egawa S
    Urol Oncol; 2015 Jul; 33(7):322-8. PubMed ID: 26070474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Degarelix: a new approach for the treatment of prostate cancer.
    Persson BE; Kold Olesen T; Jensen JK
    Neuroendocrinology; 2009; 90(3):235-44. PubMed ID: 19602868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Degarelix: a gonadotropin-releasing hormone antagonist for the management of prostate cancer.
    Steinberg M
    Clin Ther; 2009; 31 Pt 2():2312-31. PubMed ID: 20110043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide.
    Axcrona K; Aaltomaa S; da Silva CM; Ozen H; Damber JE; Tankó LB; Colli E; Klarskov P
    BJU Int; 2012 Dec; 110(11):1721-8. PubMed ID: 22500884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists.
    Klotz L; Miller K; Crawford ED; Shore N; Tombal B; Karup C; Malmberg A; Persson BE
    Eur Urol; 2014 Dec; 66(6):1101-8. PubMed ID: 24440304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Degarelix: a novel gonadotropin-releasing hormone blocker for the treatment of prostate cancer.
    Anderson J
    Future Oncol; 2009 May; 5(4):433-43. PubMed ID: 19450172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer.
    Miki K; Sasaki H; Kido M; Takahashi H; Aoki M; Egawa S
    BMC Cancer; 2016 Sep; 16(1):708. PubMed ID: 27586506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Degarelix acetate for the treatment of prostate cancer.
    Klotz L
    Drugs Today (Barc); 2009 Oct; 45(10):725-30. PubMed ID: 20069136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer.
    Crawford ED; Tombal B; Miller K; Boccon-Gibod L; Schröder F; Shore N; Moul JW; Jensen JK; Olesen TK; Persson BE
    J Urol; 2011 Sep; 186(3):889-97. PubMed ID: 21788033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GnRH antagonists in the treatment of advanced prostate cancer.
    Pommerville PJ; de Boer JG
    Can J Urol; 2010 Apr; 17(2):5063-70. PubMed ID: 20398443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists.
    Shore ND; Abrahamsson PA; Anderson J; Crawford ED; Lange P
    Prostate Cancer Prostatic Dis; 2013 Mar; 16(1):7-15. PubMed ID: 22751146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gonadotropin-releasing hormone: an update review of the antagonists versus agonists.
    Van Poppel H; Klotz L
    Int J Urol; 2012 Jul; 19(7):594-601. PubMed ID: 22416801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Testosterone surge: rationale for gonadotropin-releasing hormone blockers?
    van Poppel H; Nilsson S
    Urology; 2008 Jun; 71(6):1001-6. PubMed ID: 18407326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Degarelix for prostate cancer.
    Doehn C; Sommerauer M; Jocham D
    Expert Opin Investig Drugs; 2009 Jun; 18(6):851-60. PubMed ID: 19453267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
    Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
    BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer.
    Boccon-Gibod L; Iversen P; Persson BE
    Expert Rev Anticancer Ther; 2009 Dec; 9(12):1737-43. PubMed ID: 19954284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of gonadotrophin-releasing hormone antagonists in the treatment of patients with advanced hormone-dependent prostate cancer in the UK.
    Rosario DJ; Davey P; Green J; Greene D; Turner B; Payne H; Kirby M
    World J Urol; 2016 Dec; 34(12):1601-1609. PubMed ID: 27097892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abarelix and other gonadotrophin-releasing hormone antagonists in prostate cancer.
    Kirby RS; Fitzpatrick JM; Clarke N
    BJU Int; 2009 Dec; 104(11):1580-4. PubMed ID: 20053189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety of degarelix, a GnRH antagonist: a 12-month, multicentre, randomized, maintenance dose-finding phase II study in Japanese patients with prostate cancer.
    Ozono S; Ueda T; Hoshi S; Yamaguchi A; Maeda H; Fukuyama Y; Takeda K; Ohashi Y; Tsukamoto T; Naito S; Akaza H
    Jpn J Clin Oncol; 2012 Jun; 42(6):477-84. PubMed ID: 22457321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [GnRH antagonists--a new therapy option for advanced prostate cancer].
    Wolff JM
    Aktuelle Urol; 2009 May; 40(3):159-63. PubMed ID: 19399720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.